مباشر
FierceBiotechSanofi CFO defends Hudson’s Dupixent legacy, but accepts ‘number of setbacks’ in R&DFierceBiotechFrom debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spreeThermo FisherThermo Fisher Scientific (NYSE:TMO) Beats Q1 Estimates But Stock Drops in Pre-Market - ChartMill10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - Yahoo Finance SingaporeThermo FisherThermo Fisher posts quarterly results beat as lab products, biopharma services grow - ReutersThermo FisherTHERMO FISHER SCIENTIFIC ($TMO) Releases Q1 2026 Earnings - Quiver QuantitativeAgilentUniversal Beteiligungs und Servicegesellschaft mbH Sells 54,276 Shares of Agilent Technologies, Inc. $A - MarketBeatThermo Fisher[8-K] THERMO FISHER SCIENTIFIC INC. Reports Material Event - Stock TitanThermo FisherThermo Fisher Scientific Reports First Quarter 2026 Results - Yahoo FinanceAgilentBoston Trust Walden Corp Sells 21,880 Shares of Agilent Technologies, Inc. $A - MarketBeatThermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Borrow Rate - Xã Thanh HàAgilentIs Agilent Technologies a Better Buy Than Danaher? - Trefis
Endpoints News ٢٦ يناير ٢٠٢٦

Genmab halts enrollment for cancer drug from ProfoundBio buyout

Genmab halts enrollment for cancer drug from ProfoundBio buyout

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.